Lrh-1 modulators
US-2018243245-A1 · Aug 30, 2018 · US
Heterocyclic compound and use thereof
US10584097B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10584097-B2 |
| Application number | US-201916577449-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 20, 2019 |
| Priority date | Aug 3, 2017 |
| Publication date | Mar 10, 2020 |
| Grant date | Mar 10, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
First claim
Opening claim text (preview).
The invention claimed is: 1. N-((2S,3S)-2-((2,3′-difluorobiphenyl-3-yl)methyl)-1-(2-hydroxy-2-methylpropanoyl)pyrrolidin-3-yl)ethanesulfonamide or a salt thereof.
Assignees
Inventors
Classifications
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
linked by a carbon chain containing only aliphatic carbon atoms · CPC title
linked by a chain containing hetero atoms as chain links · CPC title
containing three or more hetero rings · CPC title
linked by a carbon chain containing aromatic rings · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10584097B2 cover?
- The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, is useful as an agent for the prophylaxis or treatment of narcolepsy.
- Who is the assignee on this patent?
- Takeda Pharmaceuticals Co
- What technology area does this patent fall under?
- Primary CPC classification C07D211/56. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 10 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 9 related publications on this page (citations in our corpus or others sharing the same primary CPC).